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Abstract 
Background: Excitotoxicity is a central pathological pathway in many neurological diseases with blood–brain barrier 
(BBB) dysfunction. Kainate, an exogenous excitotoxin, induces epilepsy and BBB damage in animal models, but the 
direct effect of kainate on brain endothelial cells has not been studied in detail. Our aim was to examine the direct 
effects of kainate on cultured cells of the BBB and to test three anti‑inflammatory and antioxidant drugs used in clini‑
cal practice, simvastatin, edaravone and dexamethasone, to protect against kainate‑induced changes.
Methods: Primary rat brain endothelial cell, pericyte and astroglia cultures were used to study cell viability by imped‑
ance measurement. BBB permeability was measured on a model made from the co‑culture of the three cell types. 
The production of nitrogen monoxide and reactive oxygen species was followed by fluorescent probes. The mRNA 
expression of kainate receptors and nitric oxide synthases were studied by PCR.
Results: Kainate damaged brain endothelial cells and made the immunostaining of junctional proteins claudin‑5 
and zonula occludens‑1 discontinuous at the cell border indicating the opening of the barrier. The permeability of 
the BBB model for marker molecules fluorescein and albumin and the production of nitric oxide in brain endothe‑
lial cells were increased by kainate. Simvastatin, edaravone and dexamethasone protected against the reduced cell 
viability, increased permeability and the morphological changes in cellular junctions caused by kainate. Dexametha‑
sone attenuated the elevated nitric oxide production and decreased the inducible nitric oxide synthase (NOS2/iNOS) 
mRNA expression increased by kainate treatment.
Conclusion: Kainate directly damaged cultured brain endothelial cells. Simvastatin, edaravone and dexamethasone 
protected the BBB model against kainate‑induced changes. Our results confirmed the potential clinical usefulness of 
these drugs to attenuate BBB damage.
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Introduction
Excitotoxicity has a pivotal role in many neurological dis-
eases, including stroke, traumatic brain injury, epilepsy 
and neurodegenerative disorders like multiple sclero-
sis, Alzheimer’s, Huntington’s and Parkinson’s diseases 
[1–3]. Glutamate is one of the most important excita-
tory neurotransmitters of the CNS, and together with 
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endogenous or exogenous excitotoxins, like N-methyl-
d-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) and kainate, act 
on specific receptor families. Receptors of glutamate 
(NMDA receptors: GluN1-3B; AMPA receptors: GluA1-
4; kainate receptors: GluK1-5; metabotropic receptors: 
mGluR1-8) are highly expressed in different brain areas 
such as cortex, limbic system, basal ganglions, hippocam-
pus and cerebellum [4]. Excitatory neurotransmitters are 
fundamental for physiological processes, but the exces-
sive stimulation of these receptors causes excitotoxic-
ity, the damage or death of the nerve cells [4]. Kainate 
is a natural glutamate analogue isolated from seaweed 
which can bind to glutamate receptors. In research kain-
ate is used to induce epilepsy in animal experiments in 
which not only excitotoxicity and neuronal damage but 
also blood–brain barrier (BBB) leakage and neurovas-
cular changes are observed [5]. Among the excitatory 
compounds the effect of glutamate and the presence of 
glutamate receptors on brain endothelial cells have been 
described previously by our group and others [6–11], but 
kainate effects and receptors are less investigated at the 
level of BBB.
Taking into account the central role of the BBB in cen-
tral nervous system (CNS) physiology [12] and neuro-
pathologies [13] the cerebral vasculature emerges as a 
therapeutic target for neurological diseases [14, 15]. Vas-
cular inflammation and oxidative stress are central path-
ways in many CNS diseases such as stroke, amyotrophic 
lateral sclerosis and epilepsy, and anti-inflammatory or 
antioxidant drugs are also used to treat them [15–17]. For 
the present study we selected three clinically used drugs, 
the anti-inflammatory simvastatin and dexamethasone, 
and the free radical scavenger edaravone. Besides their 
lipid-lowering effect, statins also exhibit neuroprotec-
tive, immunosuppressive, anticonvulsant and antioxi-
dant properties [18, 19]. The pleiotropic effects of statins 
include the inhibition of inflammatory responses and the 
improvement of endothelial functions [20]. Simvastatin 
is a lipophilic statin exerting neuroprotective effects [21], 
which also protects the BBB in an acute stroke model in 
rats [22]. Edaravone is an excellent free radical scaven-
ger molecule, which is clinically used for treating acute 
stroke and amyotrophic lateral sclerosis [17]. Our group 
demonstrated the protective effect of edaravone on brain 
endothelial cells against methylglyoxal-induced bar-
rier damage [23]. In a kainate-induced epilepsy model 
in rats edaravone significantly decreased neuronal cell 
death and hyperexcitability [24]. Dexamethasone, a syn-
thetic corticosteroid, has a strong anti-inflammatory 
and immunosuppressant effects. It also enhances barrier 
properties in culture models of the BBB, including eleva-
tion of transendothelial electrical resistance, decrease in 
paracellular permeability and upregulation of tight junc-
tion proteins [25, 26]. Dexamethasone was protective in 
animal models, too: it  decreased the BBB permeability 
and edema in kainate-induced seizures in rats [27] and 
protected the BBB from damage and reduced the severity 
of seizures in pilocarpin-induced status epilepticus [16]. 
In addition, dexamethasone exerted beneficial effects in 
pediatric drug resistant epileptic patients [16].
Our aim was to investigate the direct effect of kainate 
on culture models of the three major cell types of the 
BBB, brain endothelial cells, pericytes and astrocytes, 
and to test clinically used therapeutic molecules simv-
astatin, edaravone and dexamethasone as potential pro-
tective agents against kainate-induced brain endothelial 
damage using a BBB co-culture model.
Materials and methods
Materials
All reagents were purchased from Sigma-Aldrich Cor-
poration (subsidiary of Merck, Darmstadt, Germany), 
unless otherwise indicated. The source and catalogue 
number of the reagents are listed in Additional file  1: 
Table S1.
Cell cultures
The isolation of primary rat brain endothelial cells, glial 
cells and pericytes and the co-culture BBB model were 
done as described in our previous studies [28, 29]  and 
in Additional file 1: Detailed protocol. Primary rat brain 
endothelial cells were isolated from 3-week-old out-
bred male and female Wistar rats (Harlan Laboratories, 
USA). Following isolation cells were seeded onto collagen 
type IV and fibronectin coated (100  µg/ml each) Petri 
dishes (100  mm; Corning, USA). Cells were maintained 
in DMEM-F12 supplemented with 15% plasma-derived 
bovine serum (PDS; First Link, UK), 5  μg/ml insulin, 
5  μg/ml transferrin, 5  ng/ml sodium selenite (Pan Bio-
tech, Germany), 10 mM Hepes, 1 ng/ml basic fibroblast 
growth factor, 100  μg/ml heparin and 50  μg/ml gen-
tamycin. During the first 3  days of culture the capillary 
endothelial cells were kept in culture medium containing 
3 μg/ml puromycin to eliminate P-glycoprotein negative 
cell types [30]. Cells were used at the first passage (P1) for 
experiments.
Primary rat brain pericytes were isolated by the same 
protocol, except that puromycin treatment was not 
applied. After isolation pericytes were seeded onto col-
lagen type IV coated (100  µg/ml) Petri dishes (60  mm; 
VWR International, USA) and cultured in DMEM 
medium (Gibco, Life Technologies, USA) containing 10% 
fetal bovine serum (FBS, Pan Biotech, Germany) and 
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gentamycin (50 μg/ml). Cells were used at the third pas-
sage (P3) for experiments.
Primary rat astrocytes were obtained from 1-day-
old Wistar rats. Following mechanical dissociation of 
brain tissue and filtration, cell clusters were plated onto 
uncoated 75  cm2 flasks (TPP, Switzerland) and cultured 
in DMEM supplemented with 10% FBS and gentamycin 
(50 μg/ml) until they reached 90% confluency. Cells were 
passaged (P1) to collagen type IV (100  µg/ml) coated 
12-well plates (Corning, USA) at a cell number of 5 × 104 
cells/well and cultured for 2 weeks before use in the co-
culture model. Glia cultures included more than 90% 
GFAP immunopositive astrocytes (Additional file 1: Fig-
ure S1).
For the co-culture BBB model [31] first pericytes 
(1.5 × 104 cells/cm2) were passaged to the bottom side 
of the 12-well format culture inserts (Transwell clear, 
polyester membrane, 0.4 µm pore size, 1.12 cm2 surface; 
Corning, USA) coated with collagen type IV (100  µg/
ml), then brain endothelial cells (7.5 × 104 cells/cm2) 
were added to the upper side coated with collagen type 
IV and fibronectin (100  µg/ml each). The inserts were 
placed into 12-well plates containing confluent P1 astro-
cyte layers. Endothelial culture medium was added to 
both compartments. Cells were co-cultured for 4  days 
before experiments [30, 31]. For longer version of the cell 
culture protocol and immunostaining of pericytes (see 
Additional file 1: Detailed protocol, Figure S1).
Treatments
Rat brain endothelial cells, astrocytes and pericytes were 
treated with kainate (213  Da; 100  mM stock solution 
was prepared in sterile water by the addition of NaOH) 
at 10 µM and 100 µM concentrations in culture medium 
for 1 and 24  h, based on our preliminary experiment 
and in agreement with literature data [32]. Simvastatin, 
edaravone (for both 1  mM stock solution was prepared 
in dimethyl sulfoxide) and dexamethasone (cyclodextrin 
complex; 10  mM stock solution was prepared in sterile 
water) were applied at a concentration of 1  µM based 
on our preliminary study and literature data [21, 23, 
25]. The control group received culture medium. Triton 
X-100 (TX-100) detergent was used at 1% concentration 
in viability assays as a reference compound to cause cell 
death (Additional file  1: Figure S2). As reference com-
pounds hydrogen peroxide  (H2O2; 100 µM) was used for 
the measurement of reactive oxygen species and sodium 
nitroprusside (SNP; 100 µM) during the nitric oxide pro-
duction assay.
Real‑time cell analysis
For dynamic monitoring of living brain endothelial cells 
impedance-based cell electronic sensing was used, which 
is a non-invasive, label-free technique. This method has 
been established to follow not only cell attachment and 
growth, but cell viability as well. We have verified by end-
point colorimetric tests and morphological methods that 
impedance changes can sensitively detect cell damage 
[23, 29, 33] and protection [23, 29]. The RTCA-SP sys-
tem (ACEA Biosciences, CA, USA) registers the imped-
ance of cells automatically every 10 min. For every time 
point cell index is defined as  (Rn − Rb)/15, where  Rn is the 
impedance of the wells containing cells and  Rb means the 
background impedance of the wells containing medium 
but not cells. Cells were passaged to special 96-well 
microtiter plates with gold electrodes (E-plate, ACEA 
Biosciences, CA, USA) which were coated with collagen 
type IV and fibronectin (100  µg/ml each) for rat brain 
endothelial cells or with collagen type I (150  µg/ml) for 
rat astrocytes and pericytes. For measuring background 
impedance 50  µl culture medium was added to each 
well, then 50 µl cell suspension was seeded at a density of 
6 × 103 cells/well. When the impedance of cells reached 
a plateau phase, they were treated with kainate  and the 
selected drugs and were monitored for an additional 
24 h. As a reference compound to induce cell death Tri-
ton X-100 (TX-100) detergent was used at 1% concentra-
tion (Additional file 1: Figure S2).
Total RNA isolation and reverse transcription polymerase 
chain reaction (RT‑PCR)
Total RNA was isolated from rat brain cortex, microves-
sels and brain endothelial cells by using TriFast rea-
gent (VWR International, USA), then 1  µg RNA from 
each sample was transcribed to complementary DNA 
by Maxima First Strand cDNA Synthesis Kit (Thermo 
Fisher, USA). Previously designed specific oligonucleo-
tide primer pairs, covering different exons or exon/exon 
boundaries, were used and modified for the five rat kain-
ate receptor genes [34–36] and for the three nitric oxide 
synthase genes [37] (Additional file 1: Table S2). Primers 
for β-actin and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) genes were used as loading controls 
(Additional file  1: Table  S2). PCR was performed with 
FIREPol DNA Polymerase (Solis BioDyne, Estonia) in 
Labcycler 48  s Gradient (SensoQuest, Germany). After 
heat inactivation for 3  min at 95  °C, the cycling condi-
tions were the following: denaturation for 30 s at 95  °C, 
annealing for 30 s at the appropriate annealing tempera-
ture (Additional file 1: Table S2), polymerization for 40 s 
at 72  °C (35 cycles), final extension for 5  min at 72  °C. 
Products were analysed on 2% agarose gel (VWR Inter-
national, USA), then isolated fragments were sequence 
verified by capillary DNA sequencing. Band intensities 
on the gel photos were quantified by ImageJ software 
(National Institutes of Health, USA). The qPCR was 
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performed with 2 × Power SYBR Green PCR Master Mix 
(Applied Biosystems, USA) in a RotorGene 3000 instru-
ment (Corbett Research, Australia). After heat activa-
tion at 95  °C for 2  min the cycling conditions were the 
following: denaturation for 5  s at 95  °C, annealing and 
polymerization for 30 s at 60 °C (40 cycles). Fluorescent 
signals were collected after each extension step and at the 
end the registration of the melting curve was performed 
between 55 and 95  °C. Relative gene expression levels 
were normalized to endogenous control genes (β-actin 
and GAPDH) (ΔCt). Then ΔΔCt was calculated in com-
parison to the relative expression of the target genes in 
untreated control groups. Fold changes were calculated 
using the  2−ΔΔCt formula.
Measurement of permeability for marker molecules
Two marker molecules were used for the permeabil-
ity measurement: Evans blue-labeled albumin (EBA: 1% 
BSA + 167.5 µg/ml Evans blue; 67 kDa) and sodium fluo-
rescein (SF; 10  µg/ml; 376  Da). After treatment, inserts 
were placed into 12-well plates containing 1.5 ml Ringer–
Hepes buffer (150  mM NaCl, 2.2  mM  CaCl2, 0.2  mM 
 MgCl2, 5.2  mM KCl, 5  mM glucose, 6  mM  NaHCO3 
and 10  mM Hepes; pH 7.4) supplemented with insulin, 
transferrin and sodium selenite and 0.1% BSA. The cul-
ture medium was changed in the upper compartment 
to 0.5  ml Ringer–Hepes buffer containing EBA and SF. 
For 30  min the plates were kept on a horizontal shaker 
(150  rpm) in a  CO2 incubator then samples were col-
lected from both compartments. The concentrations of 
the marker molecules were measured by a fluorescence 
multiwell plate reader (Fluostar Optima, BMG Labtech-
nologies, Germany) at 584  nm excitation and 680  nm 
emission wavelengths for EBA, and 485  nm excitation 
and 520  nm emission wavelengths for SF. The appar-
ent permeability coefficients  (Papp) were calculated as 
described in our earlier studies [29, 38].
Measurement of reactive oxygen species and nitric oxide 
production
Chloromethyl-dichloro-dihydro-fluorescein diacetate 
(DCFDA, Molecular Probes, Life Technologies, USA) was 
used for ROS detection, and 4-amino-5-methylamino-
2′,7′-difluorofluorescein diacetate (DAF-FM, Molecular 
Probes, Life Technologies, USA) for NO detection as 
fluorescent probes, as described in our previous studies 
[39, 40]. Brain endothelial cells were cultured in 96-well 
plates with black walls and transparent plastic bottoms 
(Corning, NY, USA). After treatments for 1 or 24 h, cells 
were incubated in Ringer–Hepes buffer containing 2 µM 
DCFDA or 2 µM DAF-FM probes. Pluronic acid (Molec-
ular Probes, Life Technologies, USA; 16 µM) was used to 
help the probes crossing the cell membrane. Fluorescence 
was detected by Fluostar Optima multiwell plate reader 
(BMG Labtechnologies, Germany) at 485  nm excitation 
and 538 nm emission wavelengths at every 3 min for 1 h.
Immunohistochemistry
For the immunostaining of junctional proteins claudin-5 
and zonula occludens-1 (ZO-1) rat brain endothelial 
cells (2.5 × 104 cells/well) were grown on glass cover-
slips (1  cm2, borosilicate, VWR, USA) coated overnight 
at 4  °C with rat tail collagen (150  µg/ml). Cells treated 
with kainate and protective drugs for 24  h were fixed 
with 1% paraformaldehyde for 20  min at 4  °C, permea-
bilized with 0.2% Triton-X100 for 10  min at 4  °C, then 
blocked with 3% BSA-PBS for 1 h at room temperature. 
Samples were incubated with rabbit anti-claudin-5 poly-
clonal (SAB4502981, 1:800 dilution in 3% BSA-PBS, anti-
body registry ID: AB_10753223; Sigma-Aldrich, USA) or 
rabbit anti-ZO-1 polyclonal (61-7300, 1:400 dilution in 
3% BSA-PBS, antibody registry ID: AB_2533147; Invit-
rogen, USA) primary antibodies overnight at 4  °C, then 
with anti-rabbit secondary antibody conjugated with 
Cy3 (C2306, 1:400 dilution in PBS, antibody registry ID: 
AB_258792; Sigma-Aldrich, USA) and H33342 nucleus 
stain (1  µg/ml) for 1  h at room temperature [40]. Cells 
were washed with PBS between the incubations. Cover-
slips were mounted in Fluoromount-G (Southern Bio-
tech, USA) and visualized by Leica SP5 confocal laser 
scanning microscope. Tight junction staining patterns 
(4–7 images in each group) were analysed by MATLAB 
software (MathWorks, Natick, MA, USA). The back-
grounds of each image were determined and subtracted 
to compensate the occasional non-uniform background. 
The grayscale images were converted to binary. The 
object number reveals the number of the separated struc-
ture elements of the images, indicating discontinuity in 
the staining pattern.
Statistical analysis
Data are presented as mean ± SD or SEM. Intensity meas-
urements for nitric oxide synthase (NOS) RT-PCR were 
analysed by ImageJ software (National Institutes of Health, 
USA). Statistical analysis was done by GraphPad Prism 5.0 
software (GraphPad Software, USA). Significance between 
groups was determined using t-test or one-way ANOVA 
followed by Dunnett or Bonferroni posttests. Differences 
were considered statistically significant at p < 0.05. All 
experiments were repeated at least twice.
Results
Effect of kainate on cell viability of rat brain endothelial 
cells, astrocytes and pericytes
Viability and integrity of brain endothelial, astrocyte 
and pericyte cell layers were monitored with real-time 
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impedance measurement for 24 h after kainate treatment 
(10 and 100 μM) (Fig. 1a). Kainate at 100 μM concentra-
tion decreased endothelial cell viability compared to the 
control at both time points. Interestingly, kainate had no 
effect on cultured astrocytes and pericytes (Fig.  1b, c). 
Based on this result the 100  μM kainate treatment was 
selected for further experiments.
Expression of kainate receptors in rat brain cortex, rat 
brain microvessels and primary rat brain endothelial cells
In rat brain cortex all of the five kainate receptor genes 
were expressed (GluK1/GluR5, GluK2/GluR6, GluK3/
GluR7, GluK4/KA-1 and GluK5/KA-2) as shown in 
Fig.  2. In isolated rat brain microvessels the expression 
of GluK1 and GluK4, while in primary rat brain endothe-
lial cell cultures GluK1 expression was detected by RT-
PCR. GluK5 gene expression was also slightly detectable 
in these samples (Fig.  2). These results were verified by 
capillary DNA sequencing. The expression of housekeep-
ing genes β-actin and GAPDH were similar in rat brain 
cortex, isolated rat brain microvessel and primary rat 
brain endothelial cell samples (Additional file  1: Figure 
S3).
Effect of kainate on the permeability of the BBB co‑culture 
model
The tightness of the BBB model was tested by the 
measurement of  Papp for marker molecules fluorescein 
(4.72 × 10−6 cm/s) and albumin (0.31 × 10−6 cm/s) which 
were in the range we measured in previous studies [29, 
41]. Kainate treatment (100  μM) significantly increased 
the permeability of the BBB model for both markers at 
the 1 and 24 h time points (Fig. 3).
Effect of kainate on reactive oxygen species and nitric 
oxide production
Kainate did not show any effect on the basal ROS produc-
tion of brain endothelial cells after 1 or 24 h compared to 
the control group, but it elevated NO generation in brain 
endothelial cells after 1 h (Fig. 4). Hydrogen peroxide was 
Fig. 1 The effect of kainate on cell viability. a Cultured rat brain endothelial cells. b Rat astrocyte cultures. c Rat brain pericyte cultures after 1 h 
or 24 h treatment with kainate (KA). Control group (C) received only culture medium. Mean ± SEM, n = 3–12, ANOVA, Bonferroni‑test, **p < 0.01 
compared to the control group
Fig. 2 Expression of kainate receptors. GluK1/GluR5, GluK2/GluR6, GluK3/GluR7, GluK4/KA‑1 and GluK5/KA‑2 mRNA expression is shown in rat 
brain cortex (BR), isolated rat brain microvessels (MV) and primary rat brain endothelial cells (BEC). The predicted length of the products is shown in 
Additional file 1: Table S2. Fragments were visualized on 2% agarose gel. M: 1 Kb Plus DNA ladder
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used as a reference inducer of ROS in the assay (Fig. 4), 
as in our previous study [29], while sodium nitroprusside 
was given to increase NO production [40].
Effect of simvastatin, edaravone and dexamethasone 
on the cell viability of kainate‑treated brain endothelial 
cells
Simvastatin, edaravone or dexamethasone at 1 μM con-
centration significantly increased cell viability measured 
by the impedance assay and compared to the kainate 
treatment group (100  μM) as reflected by the elevated 
cell index of rat brain endothelial cells at 24 h timepoint 
(Fig. 5).
Effect of simvastatin, edaravone and dexamethasone 
on the permeability of kainate‑treated BBB co‑culture 
model
To test the protective molecules, the permeability meas-
urements were performed similarly as described above. In 
this assay simvastatin and edaravone significantly attenu-
ated the increased permeability for both markers caused by 
kainate treatment, while dexamethasone blocked the bar-
rier opening effect only for the transcellular marker albu-
min (Fig. 6).
Fig. 3 The effect of kainate on the permeability of the BBB co‑culture model. a Permeability for sodium fluorescein (SF; 376 Da). b Permeability 
for Evans blue‑labelled albumin (EBA; 67 kDa). Treatment with 100 µM kainate (KA) lasted for 1 or 24 h. Control groups (C) received only culture 
medium. Mean ± SD, n = 4–8, t‑test, *p < 0.05, ***p < 0.001 compared to the control group. Permeability is expressed as apparent permeability 
coefficient  (Papp)
Fig. 4 The effect of kainate treatment on primary rat brain endothelial cells. a Reactive oxygen species (ROS) production. b Nitric oxide (NO) 
production. Cells were treated with 100 µM kainate (KA) for 1 or 24 h. Control groups (C) received only culture medium. Hydrogen peroxide  (H2O2, 
100 µM) served as reference compound in the ROS measurement, and sodium nitroprusside (SNP, 100 µM) served as reference compound in the 
NO assay. Mean ± SD, n = 4–6, ANOVA and Dunnett test, *p < 0.05, ***p < 0.001 compared to the control group
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Effect of simvastatin, edaravone and dexamethasone 
on the morphology of kainate‑treated endothelial cells
The tight paracellular barrier formed by brain endothe-
lial cells in the BBB model was visualized by the con-
tinuous, belt-like pericellular localization of integral 
membrane tight junction protein claudin-5 and linker 
protein ZO-1 (Fig.  7a). In the kainate treated group 
junctional staining patterns of claudin-5 and ZO-1 were 
weaker and more fragmented at the cell border, as com-
pared to the control group, while in cells treated with 
simvastatin, edaravone or dexamethasone the staining 
patterns of tight junction proteins were more similar to 
the control group (Fig.  7a). The object number on the 
immunostained pictures significantly increased due to 
kainate treatment as compared to the control group 
indicating a disturbance in the proper localization of 
the junctional proteins. Edaravone and dexamethasone 
significantly decreased the object number compared to 
the kainate-treated group for both immunostainings, 
while simvastatin was efficient to reduce the discontin-
uous pattern of ZO-1 immunostaining (Fig. 7b, c).
Effect of simvastatin, edaravone and dexamethasone 
on reactive oxygen species and nitric oxide production 
of kainate‑treated brain endothelial cells
Although kainate did not influence the ROS production 
of brain endothelial cells we tested the effect of simv-
astatin, edaravone and dexamethasone in this experi-
ment. Here edaravone showed a strong antioxidant 
effect on the basal ROS production alone or when it 
was given together with kainate (Fig.  8a). Simvastatin 
and dexamethasone had no effect on the generation 
of ROS in brain endothelial cells. More importantly, 
dexamethasone significantly reduced the elevated NO 
production induced by short-term kainate treatment 
(Fig. 8b).
Fig. 5 The effect of kainate and protective compounds on cell 
viability of primary rat brain endothelial cells. Rat brain endothelial 
cells were treated with 100 µM kainate (KA) without or with 
simvastatin (SIM, 1 µM), edaravone (EDA, 1 µM) or dexamethasone 
(DXM, 1 µM) for 24 h. Control groups (C) received only culture 
medium. Mean ± SD, n = 4–8, ANOVA, Bonferroni test, ***p < 0.001 
compared to the control group, #p < 0.05, ##p < 0.01, ###p < 0.001 
compared to the kainate‑treated group
Fig. 6 The effect of kainate and protective compounds on the permeability of BBB co‑culture model. a Permeability for sodium fluorescein (SF; 
376 Da). b Permeability for Evans blue‑labelled albumin (EBA; 67 kDa). Primary brain endothelial cells co‑cultured with astrocytes and pericytes on 
inserts were treated with 100 µM kainate (KA) without or with simvastatin (SIM, 1 µM), edaravone (EDA, 1 µM) or dexamethasone (DXM, 1 µM) for 
24 h. Control groups (C) received only culture medium. Mean ± SEM, n = 3–9, ANOVA, Bonferroni‑test, **p < 0.01 compared to the control; #p < 0.05, 
###p < 0.001 compared to the kainate‑ treated group. Permeability is expressed as apparent permeability coefficient  (Papp) in the  % of the control 
values
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Expression of nitric oxide synthase genes in brain 
endothelial cells
The expression of all three nitric oxide synthase genes 
was detected in rat brain endothelial cell cultures with 
RT-PCR and qPCR (Fig. 9). The endothelial NOS3 and 
the neuronal NOS1 genes were highly expressed in 
rat brain endothelial cells while the inducible NOS2 
showed a low expression level (Fig.  9a). Kainate treat-
ment significantly elevated the NOS2/iNOS gene 
expression but had no effect on NOS1/nNOS and 
NOS3/eNOS mRNA expressions as detected by both 
methods. Dexamethasone attenuated the increased 
expression of NOS2/iNOS caused by kainate treatment 
while it did not modify the expression of NOS1/nNOS 
(Fig.  9). The expression level of NOS3/eNOS mRNA 
was elevated in the kainate + dexamethasone group 
measured by RT-PCR, but this result was not con-
firmed by qPCR.
Discussion
Excitotoxicity is one of the main pathological pathways 
in CNS diseases leading to both neuronal injury and BBB 
dysfunction [5, 42]. Glutamate was shown to increase 
BBB permeability and reduce the integrity of tight junc-
tions in culture models of the BBB [8, 32, 43]. Ionotropic 
glutamate receptor agonists NMDA and AMPA were also 
described to decrease resistance and increase permeabil-
ity of porcine brain endothelial cells [32]. The same team 
Fig. 7 The effect of kainate treatment on the immunostaining of tight junction proteins claudin‑5 and zonula occludens‑1 in primary rat brain 
endothelial cells. a Representative confocal microscopy images of the immunostaining of junctional proteins claudin‑5 and zonula occludens‑1 
(ZO‑1) in rat brain endothelial cells treated with 100 µM kainate (KA) alone or with simvastatin (KA + SIM, 1 µM), edaravone (KA + EDA, 1 µM) or 
dexamethasone (KA + DXM, 1 µM) for 24 h. Control groups (C) received only culture medium. Red: junctional protein staining, blue: cell nuclei. 
Arrowheads: fragmented junctional staining and gaps, asterisks: apoptotic body. n = 6–10. Scale bar: 10 µm. b The object number on the claudin‑5 
immunostained pictures was quantified by MATLAB software. c The object number on the ZO‑1 immunostained pictures was quantified by MATLAB 
software. Mean ± SEM, n = 4–7, ANOVA, Bonferroni test, *p < 0.05, **p < 0.01 compared to the control group, ##p < 0.01, ###p < 0.001 compared to the 
kainate‑treated group
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reported that kainate also induced cell damage, increased 
DNA fragmentation and cell death in this BBB model, but 
further direct effects or the presence of kainate receptors 
were not investigated.
In the present study we demonstrated that kainate 
decreased cell viability measured by impedance in brain 
endothelial cells, but not in cultures of brain pericytes or 
glial cells. While several studies confirm the sensitivity of 
cultured neurons and oligodendrocytes for kainate toxic-
ity, there are no data in the scientific literature regarding 
kainate-induced cell death in astrocyte or brain pericyte 
cultures. The kainate concentration used in our experi-
ment is high, however, both for glutamate and kainate in 
culture models of the BBB similarly high concentrations 
were applied [6, 8, 32]. Extracellular glutamate concen-
trations as high as 50 and 75 µM were measured in the 
hippocampus of human patients with epilepsy by micro-
dialysis [44] indicating that in pathological conditions 
very high concentrations of excitotoxic neurotransmit-
ters can be released.
Kainate also increased the permeability of marker mol-
ecules fluorescein and albumin across the BBB model and 
changed the staining pattern of tight junction proteins 
in brain endothelial cells. These data are in concord-
ance with the barrier opening effect of glutamate in our 
previous study [8] and with data from other groups [32, 
43]. Among the receptors mediating the effect of excita-
tory mediators several types of the AMPA, NMDA and 
metabotropic glutamate receptors were described in 
brain endothelial cells at RNA, protein or functional 
levels [6–10, 43]. In addition to these receptors, we also 
found the mRNA expression of GluK1 and GluK4 in 
isolated brain microvessels and GluK1 in cultured brain 
endothelial cells. The brain microvessel fractions con-
tain not only brain endothelial cells, but also pericytes 
and astrocytic endfeet. While brain pericytes are respon-
sive to glutamate [45], there are no data on the presence 
of kainate receptors in brain pericytes. Astroglia cells 
express GluK4/KA1 both in vivo [46] and in culture [47].
Although oxidative stress and the production of excess 
ROS contribute to the damage in excitotoxicity, and 
kainate was described to increase ROS production in 
porcine brain endothelial cells [32] in the present experi-
ments kainate had no effect on ROS production in our 
model. The higher concentration of kainate and the dif-
ferent detection method in the study of Basuroy et  al. 
may explain the dissimilarity [32]. We found that kainate 
elevated NO production and the band intensity of iNOS 
mRNA. The level of iNOS is negligible in endothelial 
cells under physiological conditions, but it is increased 
in pathologies [48]. In our study the increased mRNA 
level of iNOS also indicates the damaging effect of kain-
ate. Our observations are in accordance with previous 
results showing that kainate injection into cerebral cortex 
increased NOS activity in microvessels in rats [49].
The importance of the BBB as a therapeutic target is 
increasingly recognized and several anti-inflammatory 
or antioxidant drugs and novel molecules were identi-
fied as BBB protective on culture models [25] and intro-
duced in the therapy of disease like stroke, amyotrophic 
lateral sclerosis and epilepsy [15–17]. We demonstrated 
that simvastatin protected brain endothelial cells in the 
Fig. 8 The effect of kainate treatment on primary rat brain endothelial cells. a Reactive oxygen species (ROS) production. b Nitric oxide (NO) 
production. Cells were treated with 100 µM kainate (KA) without or with simvastatin (SIM, 1 µM), edaravone (EDA, 1 µM) or dexamethasone (DXM, 
1 µM) for 1 h. Control groups (C) received only culture medium. Hydrogen peroxide  (H2O2, 100 µM) served as reference compound in the ROS 
measurement, and sodium nitroprusside (SNP, 100 µM) was used to release NO. Mean ± SD, n = 5–13, ANOVA, Bonferroni test, **p < 0.01, ***p < 0.001 
compared to the control group, #p < 0.05, ###p < 0.001 compared to the kainate‑treated group
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viability and permeability assays against kainate-induced 
changes and also restored cell morphology. These find-
ings are in agreement with the protective effects of flu-
vastatin in BBB disruption induced by glutamate in vitro 
[43]. Simvastatin showed also neuroprotective effect 
against NMDA-induced excitotoxicity in a culture model 
[50]. Our data are in concordance with the potential 
therapeutic use of statins in epilepsy [19], stroke and 
neurodegenerative diseases [51]. Brain penetration is a 
key factor in the potential therapeutic efficacy of statins 
in neurological diseases. Statins can be ligands of solute 
carriers, like OATPs, and efflux transporters, such as 
P-glycoprotein, which were identified at the level of the 
BBB and regulate CNS drug disposition [38, 41]. In a pre-
vious study we measured the permeability of rosuvasta-
tin, pravastatin and atorvastatin on our BBB model and 
found good penetration for these molecules [41].
Edaravone was also protective against kainate induced 
damage and it reduced ROS levels and kainate-induced 
NO production in our experiments. These data confirm 
our previous results on the protective and antioxidant 
effects of edaravone on cultured brain endothelial cells 
[23]. Edaravone promoted tight junction formation in 
vascular endothelial cells [52] and exerted antioxidant 
effects during NMDA excitotoxicity on brain slices [53]. 
The protective effect of edaravone was also demonstrated 
Fig. 9 Expression of nitric oxide synthases in primary rat brain endothelial cells. a Expression of neuronal nitric oxide synthase (nNOS/NOS1), 
inducible nitric oxide synthase (iNOS/NOS2) and endothelial nitric oxide synthase (eNOS/NOS3) mRNA in primary rat brain endothelial cells 
treated with 100 µM kainate (KA) alone and with dexamethasone (KA + DXM, 1 µM) for 24 h. Control groups (C) received only culture medium. The 
predicted length of the products is shown in Additional file 1: Table S2. Fragments were visualized on 2% agarose gel. M: 1 Kb Plus DNA ladder. b 
Relative gene expression changes of nitric oxide synthases measured by qPCR. Fold change is the expression ratio compared to untreated control 
groups, where negative values mean target gene downregulation, positive values mean target gene upregulation. Mean ± SEM, n = 4, ANOVA, 
Bonferroni test, *p < 0.05 compared to the control group; #p < 0.05 compared to the kainate‑treated group
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in kainate-induced epilepsy models in rats [24, 54]. All 
these preclinical data support the BBB protective effects 
of edaravone which may contribute to its efficacy in the 
clinical treatment of acute stroke and amyotrophic lateral 
sclerosis [17].
The barrier tightening effect of dexamethasone was 
described in several studies using culture models of the 
BBB [25, 26]. Dexamethasone upregulated claudin-5 and 
ZO-1 tight junction proteins in damaged brain endothe-
lial cell cultures [55, 56] supporting our data. The obser-
vations of the present study confirm data demonstrating 
the BBB protective effects of dexamethasone obtained 
in animal models of epilepsy induced by kainate [27] 
and by pilocarpine [16]. In addition to its barrier pro-
tecting effect dexamethasone decreased NO production 
and the iNOS mRNA expression elevated by kainate in 
brain endothelial cells. In accordance with our results 
dexamethasone decreased both BBB permeability and 
iNOS activity in lipopolysaccharide-treated mice [57]. 
Although the therapeutic efficacy of dexamethasone in 
epilepsy is still controversial, it exerted beneficial effects 
in pediatric drug resistant epileptic patients [16].
Conclusion
In conclusion, we proved for the first time that the excito-
toxin kainate directly damaged cultured brain endothelial 
cells. Kainate made the immunostaining of junctional pro-
teins discontinuous at the cell border indicating the open-
ing of the BBB model. Kainate increased the permeability 
of the BBB model for marker molecules, the production of 
nitric oxide (NO) and the mRNA expression of inducible 
nitric oxide synthase (NOS2/iNOS) in brain endothelial 
cells. The presence of kainate receptors was also demon-
strated on brain endothelial cells. Simvastatin, edaravone 
and dexamethasone protected the BBB model against 
kainate-induced reduced cell viability, increased perme-
ability and morphological changes in cellular junctions. 
Dexamethasone attenuated the elevated nitric oxide pro-
duction and decreased the mRNA expression of inducible 
nitric oxide synthase (NOS2/iNOS) increased by kainate 
treatment. Our results confirmed the potential clinical 
usefulness of these drugs to attenuate BBB damage.
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